Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 16/2014

01.10.2014 | Adis Drug Evaluation

Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus

verfasst von: Kate McKeage

Erschienen in: Drugs | Ausgabe 16/2014

Einloggen, um Zugang zu erhalten

Abstract

Linagliptin (Trajenta®, Tradjenta®) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto®) is also available. This article reviews the pharmacology, therapeutic efficacy and tolerability of linagliptin in the management of type 2 diabetes, with the aim of updating its place in therapy based on recently published data. In randomized, controlled trials, oral linagliptin 5 mg once daily (or 2.5 mg twice daily when combined with metformin) improved glycaemic control when used alone or in combination with other antidiabetic agents, including metformin, a sulfonylurea, thiazolidinedione or insulin. Improvements in glycaemic control were also shown in patients with renal impairment, including severe impairment, and the elderly (aged ≥70 years). Linagliptin is the first DPP-4 inhibitor to be eliminated primarily via a nonrenal route, enabling its use without dosage adjustment in patients with any degree of renal impairment. Linagliptin is generally well tolerated and, as with other DPP-4 inhibitors, it is associated with a low risk of hypoglycaemia and has no effect on bodyweight. Some data indicate that linagliptin may have beneficial effects on cardiovascular and renal safety profiles in patients with type 2 diabetes, but more data are needed. Meanwhile, the low risk of hypoglycaemia and the nonrenal route of elimination may provide important advantages for some patient groups, including elderly or renally impaired patients.
Literatur
1.
Danaei G, Finucane MM, Gitanjali MS, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMed
2.
3.
Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.PubMed
4.
5.
6.
7.
Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2012;72(13):1793–824.PubMed
8.
Scott LJ. Linagliptin in type 2 diabetes mellitus. Drugs. 2011;71(5):611–24.PubMed
9.
Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50(26):6450–3.PubMed
10.
Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175–82.PubMed
11.
Schnapp G, Klein T, Mark M, et al. Comparative enzyme kinetic analysis of the launched DPP-4 inhibitors [abstract no. A-1986]. In: 74th Scientific Session of the American Diabetes Association; 13–17 Jun 2014; San Francisco (CA).
12.
Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3(1):10.PubMedPubMedCentral
13.
Shah P, Ardestani A, Dharmadhikari G, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013;98:E1163–72.PubMed
14.
Heise T, Larbig M, Patel S, et al. The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes. Diabetes Obes Metab. 2014;16:1036–9.PubMed
15.
Forst T, Anastassiadis E, Diessel S, et al. Effect of linagliptin compared to glimepiride on postprandial glucose metabolism, islet cell function, and vascular function parameters in patients with type 2 diabetes mellitus on ongoing metformin treatment. Diabetes Metab Res Rev. 2014. doi:10.​1002/​dmrr.​2525.PubMed
16.
Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors: from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65–84.PubMed
17.
Heise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786–94.PubMed
18.
Friedrich C, Jungnik A, Retlich S, et al. Bioequivalence of linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial. Drug Res. 2014;64:269–75.
19.
20.
Fuchs H, Tillement JP, Urien S, et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009;61(1):55–62.PubMed
21.
Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667–78.PubMed
22.
Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542–50.PubMed
23.
Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13(10):939–46.PubMed
24.
Friedrich C, Emser A, Woerle H-J, et al. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther. 2013;20(6):618–21.PubMed
25.
Inagaki N, Sheu WH, Owens D, et al. Efficacy and tolerability of linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, in people with type 2 diabetes mellitus (T2DM) and liver disease: a pooled analysis of 17 randomized placebo-controlled double-blind studies [abstract no. 192]. In: International Conference on Diabetes and Metabolism; 6–9 Nov 2013; Seoul.
26.
Tadayasu Y, Sarashina A, Tsuda Y, et al. Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus. J Pharm Pharm Sci. 2013;16(5):708–21.PubMed
27.
Friedrich C, Glund S, Lionetti D, et al. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):445–54.PubMedPubMedCentral
28.
Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab. 2012;14:1145–54.PubMed
29.
Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–67.PubMed
30.
Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14:348–57.PubMed
31.
Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010;27(12):1409–19.PubMed
32.
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–83.PubMed
33.
Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14(6):565–74.PubMed
34.
Ross SA, Rafeiro E, Meinicke T. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(9):1465–74.PubMed
35.
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74.PubMed
36.
Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(7):653–61.PubMed
37.
Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012;34(9):1909.e15–1919.e15.
38.
Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.[Erratum appears in Diabet Med. 2012 Jan; 29(1):158]. Diabet Med. 2011;28(11):1352–61.PubMed
39.
Yki-Jarvinen H, Rosenstock J, Duran-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care. 2013;36(12):3875–81.PubMedPubMedCentral
40.
McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–44.PubMedPubMedCentral
41.
Groop PH, Laakso M, Rosenstock J, et al. Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment [abstract no. 914]. Diabetologia. 2013;56(Suppl 1):S364–5.
42.
Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–23.PubMed
43.
Chen Y, Ning G, Wang C, et al. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a 24-week, randomized, phase III clinical trial [abstract no. 1159-P]. Diabetes. 2013;62:A302.
44.
Wang W, Yang J, Yang G. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin: a 24-week, randomized, phase III clinical trial [abstract no. 1177-P]. Diabetes. 2013;62:A307.
45.
Thrasher J, Daniels K, Patel S, et al. Efficacy and safety of linagliptin in Black/African American patients with type 2 diabetes: a 6-month, randomized, double-blind, placebo-controlled study. Endocr Pract. 2014;20:412–20.PubMed
46.
Bajaj M, Gilman R, Patel S, et al. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014. doi:10.​1111/​dme.​12495.PubMedPubMedCentral
47.
Ross S, Caballero A, Del Prato S, et al. A randomised controlled trial of linagliptin monotherapy versus initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes patients [abstract no. P-1104]. In: International Diabetes Federation 22nd World Diabetes Congress; 2–6 Dec 2013; Melbourne.
48.
Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(4):364–71.PubMed
49.
Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 2013;67(12):1283–93.PubMedPubMedCentral
50.
McGill JB, Barnett AH, Lewin AJ, et al. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diab Vasc Dis Res. 2014;11(1):34–40.PubMed
51.
Groop PH, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16:560–8.PubMedPubMedCentral
52.
McGill JB, Yki-Jarvinen H, Duran-Garcia S, et al. Efficacy and safety of linagliptin as add-on to basal insulin in patients with type 2 diabetes and renal impairment [abstract no. A-2349]. In: 74th Scientific Session of the American Diabetes Association; 13–17 Jun 2014; San Francisco (CA).
53.
Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–8.PubMedPubMedCentral
54.
Schernthaner G, Barnett AH, Patel S, et al. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged  ≥ 65 years. Diabetes Obes Metab. 2014. doi:10.​1111/​dom.​12321. PubMed
55.
Woerle HJ, Neubacher D, Patel S, et al. Safety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age ≥70 years) with type 2 diabetes [abstract no. 848]. Diabetologia. 2012;55(Suppl 1):S350.
56.
Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):833–43.PubMed
57.
Zeng Z, Yang J-K, Tong N, et al. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin. 2013;29(8):921–9.PubMed
58.
Davidson JA, Lajara R, Aguilar RB, et al. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diabet Res Care. 2014. doi:10.​1136/​bmjdrc-2014-000020.
59.
Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycaemia. Adv Ther. 2012;29:1005–15.PubMed
60.
Del Prato S, Taskinen M-R, Owens DR, et al. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J Diabetes Complicat. 2013;27(3):274–9.PubMed
61.
von Eynatten M, Gong Y, Emser A, et al. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol. 2013;12:60. doi:10.​1186/​1475-2840-12-60.
62.
Lehrke M, Marx N, Patel S, et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther. 2014;36:1130–46.PubMed
63.
Gomis R, Owens DR, Taskinen MR, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012;66(8):731–40.PubMed
64.
Yoon K-H, Mohan V, Crowe S, et al. Long-term safety and efficacy of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in Asian patients with type 2 diabetes mellitus (T2DM): a subgroup analysis of a large 2-year study [abstract no. 173]. In: International Conference on Diabetes and Metabolism; 6–9 Nov 2014; Seoul.
65.
Gallwitz B, Rosenstock J, Emser A, et al. Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c <7 % with no hypoglycaemia and no weight gain over 2 years. Int J Clin Pract. 2013;67(4):317–21.PubMed
66.
Gallwitz B, Rosenstock J, Patel S, et al. Regardless of the degree of glycemic control, linagliptin (LINA) has lower hypoglycemia risk than all doses of glimepiride (GLIM) at all time points over a 2-year trial [abstract no. 68-LB]. In: 73rd Annual Scientific Sessions of the American Diabetes Association; 21–25 Jun 2013; Chicago (IL).
67.
Gallwitz B, Rosenstock J, Rauch T, et al. Efficacy and safety of linagliptin and glimepiride in elderly T2DM patients insufficiently controlled with metformin. [abstract no. PD-0696]. In: International Diabetes Federation 22nd World Diabetes Congress; 2–6 Dec 2013; Melbourne.
68.
Inzucchi SE, Nauck M, von Eynatten M. Lower risk of hypoglycemia in elderly type 2 diabetes patients when linagliptin is added to basal insulin: an exploratory analysis [abstract no. 2-LB]. Diabetes. 2013;62(Suppl 1):LB1.
69.
Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3. doi:10.​1186/​1475-2840-11-3.PubMedPubMedCentral
70.
Johansen OE, Neubacher D, Seck T, et al. Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes (T2D): a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies [abstract no. 376-OR]. Diabetes. 2013;62:A96.
71.
Marx N, Rosenstock J, Kahn S, et al. Baseline characteristics of participants enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in early type 2 diabetes (Carolina) [abstract no. 2358-PO]. Diabetes. 2013;62:A602.
72.
Zinman B, Ahren B, Neubacher D, et al. Efficacy and cardiovascular (CV) safety of linagliptin as add-on to insulin in type 2 diabetes (T2D): a pooled comprehensive post-hoc analysis [abstract no. A-2306]. In: 74th Scientific Session of the American Diabetes Association; 13–17 Jun 2014; San Francisco (CA).
73.
von Eynatten M, Cooper M, Perkovic V, et al. Renal safety and outcomes with linagliptin: meta-analysis of individual data from 5466 patients with type 2 diabetes [abstract no. 913]. In: 49th Annual Meeting of the European Association for the Study of Diabetes; 23–27 Sep 2013; Barcelona.
74.
Patel DS, Schernthaner G, Barnett AH, et al. Renal safety of linagliptin in elderly patients with type 2 diabetes: analysis of pooled patient data from 7 phase 3 clinical trials [abstract no. 926]. In: 49th Annual Meeting of the European Association for the Study of Diabetes; 23–27 Sep 2013; Barcelona.
75.
76.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.PubMed
77.
American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;35(Suppl 1):S11–63.
78.
79.
Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;15:2047–58.
80.
Molitch ME, DeFronzo RA, Franz MJ, et al. American Diabetes Association. Nephrop Diabetes. 2004;27(Suppl. 1):S79–83.
81.
Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36:119–30.PubMed
82.
Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248–55.PubMed
83.
Cerosola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens. 2010;28:2357–69.
84.
Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–20.PubMed
85.
Agarwal S, Parashar A, Menon V. Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate [abstract no. 1144-125]. J Am Coll Cardiol. 2014;63(12 Suppl):A1335.
86.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.PubMed
87.
Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061–72.PubMed
88.
Scheen A. Gliptins (depeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12:545–57.PubMed
89.
Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534–9.PubMed
90.
Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14:1123–8.PubMed
91.
92.
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatic risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:48–56.PubMed
93.
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370:794–7.PubMed
94.
Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures. Diabetes Care. 2011;34:2474–6.PubMedPubMedCentral
95.
Sanz C, Vazquez P, Blazquez C, et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Matab. 2010;298:E634–43.
96.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.PubMed
97.
Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120–31.PubMed
98.
Tanaka Y, Kume S, Araki S-I, et al. Renoprotective effect of linagliptin on free fatty acids-bound albumin-induced tubulointerstitial injury in mice [abstract no. A-2348]. In: 74th Scientific Session of the American Diabetes Association; 13–17 Jun 2014; San Francisco (CA).
99.
Nakaoka H, Nishida M, Nakagawa-Toyama Y, et al. Linagliptin improves the prognosis of ischaemic cardiomyopathy in a new murine model of diet-induced myocardial infarction [abstract no. A02361]. In: 74th Scientific Session of the American Diabetes Association; 13–17 Jun 2014; San Francisco (CA).
100.
Ring A, Port A, Graefe-Mody EU, et al. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol. 2011;72(1):39–50.PubMedPubMedCentral
Metadaten
Titel
Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus
verfasst von
Kate McKeage
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 16/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0308-3

Weitere Artikel der Ausgabe 16/2014

Drugs 16/2014 Zur Ausgabe

Review Article

Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations

Adis Drug Evaluation

Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C

Adis Drug Evaluation

Clevidipine: A Review of Its Use for Managing Blood Pressure in Perioperative and Intensive Care Settings

Current Opinion

Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes?

R&D Insight Report

Pembrolizumab: First Global Approval

Review Article

Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome